Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus.


Autoria(s): Misstear K.; McNeela E.A.; Murphy A.G.; Geoghegan J.A.; O'Keeffe K.M.; Fox J.; Chan K.; Heuking S.; Collin N.; Foster T.J.; McLoughlin R.M.; Lavelle E.C.
Data(s)

2014

Resumo

Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus.

Identificador

http://serval.unil.ch/?id=serval:BIB_9567E0F4BC9B

isbn:1537-6613 (Electronic)

pmid:24273045

doi:10.1093/infdis/jit636

isiid:000334689700021

Idioma(s)

en

Fonte

Journal of Infectious Diseases, vol. 209, no. 9, pp. 1479-1484

Palavras-Chave #vaccine; Staphylococcus aureus; cellular immunity; mucosal; adjuvant; nanoparticle
Tipo

info:eu-repo/semantics/article

article